BioSpace News Archive

FIRE1 today announced that it has completed patient enrollment in the U.S. Early Feasibility Study (FUTURE-HF2) of its FIRE1™ System for remote heart failure monitoring.

Skyhawk Therapeutics, Inc., a clinical-stage biotechnology company developing novel small molecule RNA splicing modifiers, today announced that the Phase 1 multiple ascending dose (MAD) portion of its Phase 1 clinical study has now begun in Australia for the company’s SKY-0515 small molecule candidate targeting Huntington’s disease (HD).

Spero Therapeutics, Inc. (Nasdaq: SPRO) today announced that it has received clearance by the U.S. Food and Drug Administration (FDA) for its investigational new drug (IND) application, to evaluate SPR206 in a Phase 2 clinical study.

Recludix Pharma, a leader in platform approaches to discover inhibitors of challenging targets for inflammatory disease and cancer, announced that members of Recludix’s management will host meetings at two investor conferences in March.

Ovid Therapeutics Inc. (NASDAQ: OVID) today announced that management will participate in a panel titled “Orphan Epilepsies” at the TD Cowen 44th Annual Health Care Conference on Wednesday, March 6, 2024, at 10:30 a.m. ET in Boston, Massachusetts.

Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need, today announced that the U.S. Food and Drug Administration (FDA) has accepted the filing of the New Drug Application (NDA) for govorestat (AT-007) for the treatment of Classic Galactosemia.

Crinetics Pharmaceuticals, Inc. announced that it has agreed to sell 8,333,334 shares of its common stock at a price of $42.00 per share to a select group of institutional and accredited healthcare specialist investors in an oversubscribed private placement.

Ocugen, Inc. announced that the Clinical Showcase webcast from the February 21, 2024 live event is now available in the Events & Presentations section of the Ocugen website.

RRD International has announced today that it launched its new brand RRD Biopharma Development reflecting its unique offering of delivering strategy-driven product development services to biopharmaceutical companies and investors.

Edgewise Therapeutics, Inc. today announced that the company will present data on EDG-5506, an investigational therapy designed to protect injury-susceptible fast skeletal muscle fibers in dystrophinopathies, at the Muscular Dystrophy Association Clinical and Scientific Conference.